We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: February 8, 2006
Last Update Posted: January 8, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Instituto Fernandes Figueira
Information provided by (Responsible Party):
Maria Elisabeth Lopes Moreira, Oswaldo Cruz Foundation
The use of intravenous immunoglobulin G (IVIG) therapy has been reported in hyperbilirubinemia of Rh hemolytic disease but we don't have enough evidences for it. Human Immunoglobulin is considered an alternative to delay the hemolytic process and consequently reduce the number of exchange transfusions and transfusions of red cells concentrate, thus diminishing the risk of transmitting transfusional therapies-related diseases. OBJECTIVE: To determine the effect of IVIG in decreasing the incidence and severity of neonatal immune hemolytic jaundice due to Rh hemolytic disease reducing the need for exchange transfusion as a primary goal in these babies. METHODS: This will be a randomized, double blind, clinical trial involving all newborns with risk of significant hyperbilirubinemia due to direct Coombs-positive Rh hemolytic disease. The primary goal will be need for exchange transfusion and others are: incidence of late anemia, kernicterus and deafness Babies were randomly assigned into two groups: group 1 (study group) received phototherapy plus IVIG (500 mg/kg); and group 2 (control group) received phototherapy and normal saline solution (10 ml/Kg) in the first 6 hours of life. Exchange transfusion was carried out in any group if at any time the bilirubin level reached 340 micromol/l (20 mg/dl) or more, or rose by 8.5 micromol/l per h (0.5 mg/dl per h). Adverse effects will be related in two groups. Parents informed consent will be asked in pre-natal time.

Condition Intervention Phase
Hyperbilirubinemia Erythroblastosis, Fetal Drug: Intravenous Immunoglobulin Drug: Normal saline solution Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 4 Study of Use of High-dose Intravenous Immune Globulin for Prevent Hyperbilirubinemia Due Rh Hemolytic Disease in Newborns Infants

Resource links provided by NLM:

Further study details as provided by Maria Elisabeth Lopes Moreira, Oswaldo Cruz Foundation:

Primary Outcome Measures:
  • Need of Exchange Transfusion [ Time Frame: 10 DAYS OF LIFE ]

Enrollment: 92
Study Start Date: October 2006
Study Completion Date: August 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Experimental group
Intravenous Immunoglobulin
Drug: Intravenous Immunoglobulin
Intravenous Immunoglobulin
Other Name: Immunoglobulin
Placebo Comparator: CONTROL GROUP
Normal Saline solution
Drug: Normal saline solution
Normal saline solution 10 ml/Kg
Other Name: saline solution

  Show Detailed Description


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 6 Hours   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All newborns with a gestational age equal or higher than 32 weeks, with a Rh (D) positive blood type, children of sensitized Rh (D) negative mothers, regardless if they were submitted or not to an intra-uterus transfusion.

Exclusion Criteria:

  • Newborns in serious condition, hydropic, hemodynamically instable or with indication for exchange transfusion at birth. The indications for exchange transfusion at birth are: presence of bilirubin in the umbilical cord higher or equal to 4mg%; hydrops, cardiac insufficiency secondary to severe anemia.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00288600

Maria Elisabeth L Moreira
Rio de janeiro, Brazil, 22420040
Sponsors and Collaborators
Oswaldo Cruz Foundation
Instituto Fernandes Figueira
Principal Investigator: Maria EL Moreira, MD Oswaldo Cruz Foundation
  More Information

Responsible Party: Maria Elisabeth Lopes Moreira, MD, PhD, Oswaldo Cruz Foundation
ClinicalTrials.gov Identifier: NCT00288600     History of Changes
Other Study ID Numbers: ivig01
First Submitted: February 6, 2006
First Posted: February 8, 2006
Results First Submitted: July 20, 2015
Results First Posted: January 8, 2016
Last Update Posted: January 8, 2016
Last Verified: December 2015

Keywords provided by Maria Elisabeth Lopes Moreira, Oswaldo Cruz Foundation:
Immunoglobulins, Intravenous
Erythroblastosis, Fetal
Exchange Transfusion, Whole Blood

Additional relevant MeSH terms:
Erythroblastosis, Fetal
Pathologic Processes
Fetal Diseases
Pregnancy Complications
Hematologic Diseases
Infant, Newborn, Diseases
Immune System Diseases
Pharmaceutical Solutions
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Immunologic Factors
Physiological Effects of Drugs